World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025

D-Index & Metrics

Best Scientists

D-Index
186
Citations
141379
World Ranking
488
National Ranking
319

Medicine

D-Index
178
Citations
128059
World Ranking
390
National Ranking
243

Michael J. Keating publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael J. Keating sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,354 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael J. Keating D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael J. Keating sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 178 D-Index — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2025 - Research.com Best Scientists Award

Overview

Michael J. Keating is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily spans the field of medicine, with a focus on genetics, pathology and forensic medicine, immunology, oncology, and epidemiology.

The scientist's work covers key topics including chronic lymphocytic leukemia research, lymphoma diagnosis and treatment, inflammatory bowel disease, immunodeficiency and autoimmune disorders, microscopic colitis, advanced breast cancer therapies, and liver diseases and immunity.

Michael J. Keating has contributed to several recent publications, among which are:

  • Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors (2020, New England Journal of Medicine)
  • Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia (2021, JAMA Oncology)
  • A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL (2022, Blood Advances)
  • AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia (2020, Clinical Cancer Research)
  • Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up (2023, Blood)

Frequent collaborators include:

  • William G. Wierda
  • Alessandra Ferrajoli
  • Nitin Jain
  • Philip A. Thompson
  • Jan A. Burger

The scientist's publications appear predominantly in journals such as:

  • Blood
  • Journal of Crohn's and Colitis
  • Leukemia
  • Clinical Lymphoma Myeloma & Leukemia
  • Leukemia & lymphoma/Leukemia and lymphoma

Best Publications

  • Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

    George Adrian Calin;Calin Dan Dumitru;Masayoshi Shimizu;Roberta Bichi

  • Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment

    Bruce D. Cheson;John M. Bennett;Michael Grever;Neil Kay

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

    Enli Liu;David Marin;Pinaki Banerjee;Homer A. Macapinlac

  • Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

    Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien

  • Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

    I F Khouri;M Keating;M Körbling;D Przepiorka

  • Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

    Michael J. Keating;Susan O'Brien;Maher Albitar;Susan Lerner

  • CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

    Barbara Savoldo;Carlos Almeida Ramos;Carlos Almeida Ramos;Enli Liu;Martha P. Mims

  • Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

    Michael J. Keating;Ian Flinn;Vinay Jain;Jacques-Louis Binet

  • Superoxide dismutase as a target for the selective killing of cancer cells

    Peng Huang;Li Feng;Elizabeth A. Oldham;Michael J. Keating

  • ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

    Laura Z. Rassenti;Lang Huynh;Tracy L. Toy;Liguang Chen

  • Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia.

    Rui Hua Xu;Helene Pelicano;Yan Zhou;Jennifer S. Carew

  • Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

    B D Cheson;P A Cassileth;D R Head;C A Schiffer

  • Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

    Alvaro Aguayo;Hagop M Kantarjian;Taghi Manshouri;Cristi Gidel

  • Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaA in Chronic Myelogenous Leukemia

    Moshe Talpaz;Hagop M. Kantarjian;Kenneth McCredie;Jose M. Trujillo

  • Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

    Hagop M Kantarjian;Susan O'Brien;Terry L. Smith;Jorge E Cortes

  • Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

    Constantine S. Tam;Susan O'Brien;William Wierda;Hagop Kantarjian

  • Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

    Hagop Kantarjian;Deborah Thomas;Susan O'Brien;Jorge Cortes

  • Rituximab Dose-Escalation Trial in Chronic Lymphocytic Leukemia

    Susan M. O’Brien;Hagop Kantarjian;Deborah A. Thomas;Francis J. Giles

Frequent Co-Authors

Susan O'Brien
Susan O'Brien University of California, Irvine
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Alessandra Ferrajoli
Alessandra Ferrajoli The University of Texas MD Anderson Cancer Center
Jan A. Burger
Jan A. Burger The University of Texas MD Anderson Cancer Center
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Elihu H. Estey
Elihu H. Estey University of Washington
Nitin Jain
Nitin Jain The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The healthcare field offers numerous online educational options for those seeking flexible study paths and diverse career opportunities. One popular choice is the RN to BSN pathway, which helps registered nurses advance their careers with a bachelor’s degree. Prospective students often look for the average cost of rn to bsn programs to understand the investment required and to find affordable options.

For individuals without a nursing background, there are also entry level msn programs online that provide a direct route to advanced nursing roles. These fast-tracked programs can be ideal for career changers who want to enter nursing at the graduate level.

Those looking for more accessible program options may be interested in the easy nursing programs to get into, which can help students enter the medical field with fewer barriers to admission.

Not all healthcare careers require direct patient care. Some prefer the administrative side, such as medical billing and coding. There are online medical billing and coding schools that accept fafsa, making these courses more financially accessible.

Best Scientists Citing Michael J. Keating

Trending Scientists

Recently Published Articles